Surveillance and Reporting
- SARS Surveillance (Jan 8, 2004)
Supplement B of Public Health Guidance for Community-Level Preparedness and Response to SARS - In the Absence of SARS-CoV Transmission Worldwide: Guidance for Surveillance, Clinical and Laboratory Evaluation, and Reporting Version 2 (Jan 21, 2004)
- Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS) (Dec 12, 2003)
MMWR 52(49);1202-1206 - SARS Case Reporting Form (Jan 8, 2004)
Appendix B2, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to SARS - SARS Case Count
During November 2002-July 2003, a total of 8,098 probable SARS cases were reported to the World Health Organization (WHO) from 29 countries. In the United States, only 8 cases had laboratory evidence of infection with SARS-CoV. Since July 2003, when SARS-CoV transmission was declared contained, active global surveillance for SARS-CoV disease has detected no person-to-person transmission of SARS-CoV. CDC has therefore archived the case report summaries for the 2003 outbreak.
During the 2003 epidemic, CDC and the Council of State and Territorial Epidemiologists (CSTE) developed surveillance criteria to identify persons with SARS in the United States. The surveillance case definition changed throughout the epidemic, to reflect increased understanding of SARS-CoV disease. The revised CSTE case definition issued on November 3, 2003, and subsequently adopted by CDC (refer to Revised U.S. Surveillance Case Definition for SARS and Update on SARS Cases --- United States and Worldwide, December 2003) will be the basis for ongoing SARS surveillance.
Archived Case Counts (2003): Worldwide (WHO) | U.S. (CDC)
Related Pages
- Clinicians and Healthcare Settings
- Community Containment, Including Quarantine
- App B1: Revised CSTE Surveillance Case Definition, Supplement B, Appendix 1 of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance: Case Definition and Status as a Nationally Notifiable Disease, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance - Plan for Surveillance of Cases of SARS-CoV Disease, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance - Plan for Surveillance of Contacts of SARS Cases, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance - Information Management, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance - Lessons Learned, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance - Rationale and Goals, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance - Reporting of Cases of SARS-CoV Disease, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- Sup B: Surveillance - Summary, Supplement B of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
- App F6 - Guidelines for Medical Surveillance of Laboratory Personnel, Supplement F, Appendix 6 of Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348
8am-8pm ET/Monday-Friday
Closed Holidays - cdcinfo@cdc.gov